Updated Jul 16, 2026
Mano Michael has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $37K.
Michael Mano is the Senior Vice President and General Counsel of Karyopharm Therapeutics Inc., a company focused on developing novel cancer therapies. He has been involved in the company's legal and compliance matters, contributing to its operations in the pharmaceutical industry.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-15 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 266 | $9.50 | $3K |
| 2026-05-15 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 700 | $0.00 | |
| 2026-03-03 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 3.5K | $9.41 | $33K |
| 2026-02-03 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 32.4K | $0.00 | |
| 2025-10-15 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 43.6K | $0.00 | |
| 2025-09-12 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 234 | $6.43 | $2K |
| 2025-09-12 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 612 | $0.00 |
Michael Mano is the Senior Vice President and General Counsel of Karyopharm Therapeutics Inc., a company focused on developing novel cancer therapies. He has been involved in the company's legal and compliance matters, contributing to its operations in the pharmaceutical industry.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($37K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Mano Michael profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.